Amanote Research
Register
Sign In
Time on Therapy for at Least Three Months Correlates With Overall Survival in Metastatic Renal Cell Carcinoma
Cancers
- Switzerland
doi 10.3390/cancers11071000
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
July 17, 2019
Authors
Unknown
Publisher
MDPI AG
Related search
Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience
World Journal of Oncology
Cancer Research
Oncology
Mp28-09 Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma and Tumor Thrombus – Trends and Effect on Overall Survival
Journal of Urology
Urology
A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma
Journal of Clinical Medicine Research
Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma
Urology
Urology
Molecular Subtyping of Metastatic Renal Cell Carcinoma: Implications for Targeted Therapy
Molecular Cancer
Cancer Research
Oncology
Molecular Medicine
Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
Survival of Patients Receiving Systematic Therapy for Metachronous or Synchronous Metastatic Renal Cell Carcinoma: A Retrospective Analysis
BMC Cancer
Cancer Research
Oncology
Genetics
A Five-Gene Signature Predicts Overall Survival of Patients With Papillary Renal Cell Carcinoma
PLoS ONE
Multidisciplinary
Mp03-08 Comprehensive Analysis and Validation of Contemporary Survival Prognosticators in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy
Journal of Urology
Urology
